Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
venetoclax + daunorubicin + cytarabine + midostaurin
- Development stage
- Unknown
- Lead developer
- CHU de Bordeaux
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Venetoclax + 3+7 + Midostaurin is an investigational four-drug combination regimen being evaluated for the treatment of newly diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) in patients eligible for intensive chemotherapy. The regimen integrates venetoclax (a BCL-2 inhibitor) and midostaurin (a multi-kinase/FLT3 inhibitor) with the standard "3+7" intensive induction chemotherapy backbone, which typically consists of three days of an anthracycline (such as daunorubicin) and seven days of cytarabine. This combination is currently being studied in the Phase 1/2 MIDOVEN trial, sponsored by University Hospital, Bordeaux, with the aim of improving complete remission rates and survival outcomes by simultaneously targeting multiple survival pathways in leukemic cells.
- Other names
- venetoclax + 3+7 + midostaurinVEN + 3+7 + MIDOvenetoclax plus intensive chemotherapy plus midostaurin
02
Targets
DNA polymerase familyBCL-2 (BCL-2 family)PRKCI (Protein kinase C iota)DNAVEGFR2 (Vascular endothelial growth factor receptor 2)TOP2A (DNA topoisomerase II)PDGFR (PDGFR family)SYK (Spleen Tyrosine Kinase)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on venetoclax + daunorubicin + cytarabine + midostaurin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on venetoclax + daunorubicin + cytarabine + midostaurin.